Titre:
  • Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Auteur:Tsourdi, Elena; Zillikens, Maria Carola Carola M.C.; Meier, Christian; Body, Jean-Jacques; Gonzalez Rodriguez, Elena; Anastasilakis, Athanasios A.D.; Abrahamsen, Bo; Mccloskey, Eugene; Hofbauer, Lorenz Christian; Guañabens, Nuria; Obermayer-Pietsch, Barbara; Ralston, Stuart; Eastell, Richard; Pepe, Jessica; Palermo, Andrea; Langdahl, Bente
Informations sur la publication:The Journal of clinical endocrinology and metabolism, 106, 1, page (264-281)
Statut de publication:Publié, 2021-01
Sujet CREF:Biochimie
Endocrinologie
Diabétologie
Métabolisme
Médecine clinique [chimie clinique]
Mots-clés:bisphosphonates
bone mineral density
bone turnover markers
denosumab
fractures
osteoporosis
teriparatide
Note générale:SCOPUS: ar.j
DecretOANoAutActif
Langue:Anglais
Identificateurs:urn:issn:0021-972X
info:doi/10.1210/clinem/dgaa756
info:scp/85100241288
info:pmid/33103722